Objective This study compares two methods of evaluating paraaortic node involvement in locally advanced cervical cancer (LACC) in order to define external radiotherapy treatment fields: laparoscopic surgical para-aortic lymphadenectomy or PET-CT imaging.
Introduction
Patients with locally advanced cervical cancer (LACC) are currently treated with chemo-radiation therapy.
1 This treatment combines external beam radiation therapy and cisplatin-based chemotherapy (40 mg/m 2 weekly) followed by intra-cavitary brachytherapy to improve the local response and reduce the rate of local relapses. 2 Lymph node status and, in particular, para-aortic lymph node involvement at initial assessment is the pivotal information for external radiotherapy, as it defines the extent of radiation fields.
Currently, para-aortic surgical lymphadenectomy can be used to assess lymph node status. 3 Laparoscopic extra-peritoneal or trans-peritoneal approach is feasible and safe in a well-trained team 4 with around a 9% complication rate. 5 However, one prospective study demonstrated that surgical staging may cause a delay to starting the chemo-radiation therapy, with a potential negative effect on survival. 6 To date, no comparative study has proven any survival benefit by this approach. 7 There is a lack of evidence to encourage systematic surgical staging pretreatment in LACC, in particular in the era of positron emission tomography (PET) imaging.
To date, PET-CT (computed tomography) is the best performing imaging tool to evaluate para-aortic lymph node involvement, with a sensitivity of 85% and a specificity of 95% for detecting nodal para-aortic metastasis. 8 However, with PET-CT, false-negative results for para-aortic node involvement have been observed in 12% of patients with LACC, mainly due to the failure in micrometastasis (<5 mm) detection. 9 The aim of this study was to compare two different methods of evaluating para-aortic node involvement in order to define the radiotherapy external field: laparoscopic surgical para-aortic lymphadenectomy and PET-CT imaging.
Methods

Patients
We identified patients with LACC who were treated from January 2001 to December 2013 in two tertiary cancer centres in France: Centre Jean Perrin in Clermont-Ferrand and Institut Claudius Regaud in Toulouse.
The endpoint of the study was patient overall survival (OS) and disease-free survival (DFS), defined as the timeperiod between initial treatment and death and local/distant recurrence, respectively.
Oncological treatment
All patients had an MRI (magnetic resonance imaging) prior to treatment. Patients were treated according to international guidelines 10 including pelvic conformational radiotherapy at the total dose of 45 Grays (25 fractions) in 5 weeks with a concomitant 40 mg/m 2 weekly base of cisplatinum followed by brachytherapy. Pulse dose rate (PDR) brachytherapy was administered at the dose of 15 Grays on the intermediate risk clinical target volume (IRCTV) and 37.5 Grays on the high risk clinical target volume (HRCTV) according to Oncologic Group GEC-ESTRO recommendations.
11
The para-aortic extended field radiation of 45 Grays was assessed by two different approaches according to the centres. In Centre 1, the para-aortic lymph nodes status was determined by PET-CT imaging only, whereas in Centre 2 it was determined by surgical para-aortic lymphadenectomy. In the first cohort, irradiation fields were extended if there was any involvement of the para-aortic, common iliac or bilateral iliac lymph nodes (Supporting Informarion Figure S1 ).
Data collection
The accrual data collection was retrospective: all patients diagnosed with an LACC were included. Demographic and clinical data including age at diagnosis, body mass index (BMI) and WHO (World Health Organization) status, and the date of first treatment were collected. We also recorded tumour histologic subtype and MRI stage based on the 2009 International Federation of Gynaecology and Obstetrics (FIGO) classification at diagnosis. Patients' oncological status at last medical visit was also assessed: remission, recurrence or death.
Statistical analysis
Descriptive parameters were expressed as a mean (AESD) and median [range] when indicated. Because patient lymph node evaluation varied according to the hospital, a comparison of the two cohorts was performed on main endpoints and clinical parameters. Categorical factors were analysed using Chi-square or Fisher's exact tests, and continuous variables with unpaired t-test. OS and DFS were calculated using the Kaplan-Meier method and survival curves were compared using log-rank test. To adjust on possible confounding factors, the effect of the different para-aortic lymph node evaluation methods on survival was evaluated by multivariate analysis: Cox regression model was used in a backward stepwise manner. Tests associated with a two-sided P-value <0.05 were considered significant. SEM software was used to compute the statistics. 12 
Results
Patients and tumour description
We collected data from 187 women treated for an LACC from January 2001 to December 2015. 98 women were managed in Centre 1 (cohort 1) and 89 in Centre 2 (cohort 2). The WHO status was statistically better in cohort 2 (P = 0.02). Para-aortic lymph node involvement was evaluated by PET CT for 87 (88.7%) patients in Centre 1, whereas it was done in all cases by laparoscopy in Centre 2 (100% of patients). When patients did not have PET CT in Centre 1, para-aortic status was determined by MRI or CT scan. Fourteen patients (14.2%) of cohort 1 were considered to be positive in the para-aortic areas based on imaging and 23 patients (25.8%) of cohort 2 had positive histological findings. Furthermore, eight patients of cohort 1 received para-aortic irradiation according to local guidelines, as three had high common iliac involvement and five had bilateral iliac lymph node involvement.
We noted a similar proportion of chemo-radiotherapy and extended chemo-radiation therapy in the two centres (respectively 96.9 and 22.4% in Centre 1, and 95.5 and 2.5% in Centre 2). The average delay between surgery and RCT was 22 days in cohort 2. In addition, 94.9% of the Centre 1 population received brachytherapy and 76.5% of the Centre 2 population (P = 0.0002). Completion surgery was practised less often in Centre 1 than in Centre 2 (11.2 and 34.8%, respectively; P = 0.0001; data provided in Table 1) .
Tumour characteristics are summarised in Table 2 . Our data showed significantly less squamous cell carcinoma and more adenocarcinoma histological subtypes in Centre 1 than in Centre 2 (respectively 704 and 27.5% in Centre 1, and 88.8 and 7.9% in Centre 2; P = 0.0005). Nevertheless, the FIGO stage was similar in the two cohorts (P = 0.3), although we noted a trend towards fewer stage II cases in cohort 2 than in cohort 1 (59.6 versus 73.5%).
Patients' survival
The mean and median patient follow up was 35.6 and 32.2 months in cohort 1 versus 43.4 and 45.7 months in cohort 2 (P = 0.02), respectively.
Our results showed a significantly better disease-free survival for patients treated in cohort 1 than in cohort 2, at 2 years Figure S2 ). Multivariate analysis supported these results, with a higher relative risk of recurrence for patients treated in cohort 2 when DFS was adjusted based on the following variables: WHO status, para-aortic involvement, brachytherapy treatment, extended chemo--radiation therapy, completion surgery, FIGO stage and histological tumour subtype (HR 1.93; 95% CI 1.03-3.61; P = 0.04) (Supporting Information Figure S3 ). In this analysis, FIGO stage was also associated with a higher risk of recurrences (P = 0.008).
Although the study revealed a better overall survival for cohort 1 than cohort 2 patients at 2 years and 5 years Figure S4 ). The multivariate analysis model found concordant results with an increased relative risk of death for patients treated in cohort 2 (HR 2.55; 95% CI 1.09-5.99; P = 0.01) (Supporting Information Figure S5 ). In this model, FIGO stage and absence of brachytherapy were also associated with a poorer survival (P = 0.03 and P = 0.05, respectively).
Discussion
Main findings
Our results have shown a better DFS and OS for patients with a LACC treated in cohort 1 than those treated in cohort 2, where the main difference between the two cohorts was in the method used to determine para-aortic lymph node involvement: laparoscopic para-aortic lymphadenectomy in Centre 2 versus PET-CT in Centre 1.
Strengths
This study used the same study design as the SEPAL study, which investigated a difference in the surgical management of endometrial carcinoma between two cancer centres. 13 In our study, both centres have more than 20 years' experience of laparoscopy in the field of gynaecology oncology and lack of experience was not a reason for the difference between the two assessment strategies.
To the best of our knowledge, this is the first study since the randomised control trial (RCT) by Lai et al. in 2003, 6 which compared the two methods for detecting para-aortic lymph node involvement. 7 Similar to our study, Lai et al. found that women who underwent surgical staging had a significantly higher risk of death and persistent or recurrent disease compared with women who underwent radiological staging. This RCT did not provide convincing evidence and received much criticism from the oncological community, mostly because women in the surgical arm had significantly poorer pretreatment risk factors. On the contrary, in our study, FIGO stage was comparable between the two groups, and patients in cohort 1 were older, with a higher BMI, a worse WHO status and a greater proportion with an adenocarcinoma histological subtype (considered to be more aggressive). 14 
Limitations
As limitations, we recognise the non-randomised, retrospective nature of our study.
A number of studies do support the rationale of surgical staging versus radiographic assessment of para-aortic lymph node metastases before chemo-radiation for locally advanced cervical carcinoma. In a study including 685 patients from three different randomised GOG trials, Gold et al. 15 demonstrated that even if patients in the radiology group had less advanced disease, smaller tumour size and better performance status, DFS and OS were significantly improved in the surgical group. In a recent randomised controlled trial involving 121 patients, they found that surgical staging is safe and does not delay primary RCTX. 16 In our study, the number of patients with para-aortic involvement was similar between the two cohorts. In cohort 1, 14/98 (14.2%) patients were considered positive in the para-aortic area by PET-CT. When we apply the estimated false-negative rate of PET-CT of 12%, it hypothetically increases the number of positive para-aortic lymph node in cohort 1 to a rate that is similar to cohort 2 (25.8%). In addition, although the rate of brachytherapy was significantly higher in Centre 1 when patients who did not receive brachytherapy were excluded from the univariate analysis, the DFS was still significantly better in Centre 1, with a trend towards better survival in Centre 1 but no statistical difference in OS between the two cohorts. Furthermore, although brachytherapy was associated with better overall survival, it was not associated with fewer recurrences in the multivariate analysis model. There was a higher rate of completion surgery in Centre 2 but this variable had no impact in multivariate analysis on DFS or OS, which would appear consistent with the literature. [17] [18] [19] Interpretation Based on our study results, determination of para-aortic lymph node involvement using surgical lymphadenectomy appears to be deleterious for patients with LACC in terms of both OS and DFS. There are several hypotheses to explain this observation.
First, the potentially increased delay between the diagnosis and the therapeutic intervention is induced by surgery. 6 As Chantalat et al. 20 showed in his retrospective study on LACC with para-aortic involvement, most recurrences were distant and rarely para-aortic, suggesting the existence of occult metastasis disease at the outset. Therefore, in these cases, early systemic treatment would appear important when there is para-aortic lymph node involvement.
Secondly, no study has yet shown a clear benefit of extended-field radiotherapy on survival following the introduction of cisplatin systemic therapy in the initial management of LACC. As Fyles et al. showed in his randomised trial comparing PET-CT and CT alone in LACC, despite PET-CT resulting in an increase in the percentage of patients receiving more extensive radiation, no clear difference in overall survival between the two arms was detected. Extended-field radiotherapy appeared to give no survival benefit in this study. 21 Moreover Eifel et al. 22 when comparing pelvic irradiation with concurrent chemotherapy with pelvic and para-aortic irradiation alone in LACC showed a clear benefit of the addition of chemotherapy in improving overall survival for these patients. In these cases, it is probably not a question of extending local therapy but rather the additional systemic treatment that may be more beneficial.
Thirdly, there is the question of whether para-aortic lymphadenectomy without removal of the primary tumour may be deleterious for patients because of its adverse immunological effects. We have known for some time that surgery creates an inflammatory environment, with an increase in growth factor secretion and an immunosuppressive state which could be favourable to tumour development and metastasis emergence. 23, 24 This theory is all the more valid if the primary tumour is still present; in fact, there are no other solid tumours for which such a surgery is practised.
We recommend that para-aortic lymphadenectomy is not performed outside of a randomised clinical trial to demonstrate that surgical staging is of benefit for patients. Frumovitz et al. initiated the LILACS study, which aimed to compare radiological with surgical staging in LACC; although currently abandoned, it is hoped that it will be reactivated in the near future. 25 
Conclusion
In this retrospective comparative analysis, we have shown that PET-CT staging in LACC is more beneficial for patients than surgical staging in terms of OS and DFS.
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